Similar prevalence of platelet factor 4/heparin immunoglobulin G antibodies in patients following cardiac surgery and other patients suspected of heparin-induced thrombocytopaenia

Published on Sep 7, 2018in Kardiologia Polska1.674
· DOI :10.5603/KP.2018.0184
Agata Hanna Bryk3
Estimated H-index: 3
(Jagiellonian University Medical College),
Piotr Mazur6
Estimated H-index: 6
(Jagiellonian University Medical College)
+ 5 AuthorsAnetta Undas41
Estimated H-index: 41
(Jagiellonian University Medical College)
  • References (0)
  • Citations (1)
Cited By1
#1Konrad Stepien (Jagiellonian University Medical College)
#2Karol Nowak (Jagiellonian University Medical College)
Last. Anetta Undas (Jagiellonian University Medical College)H-Index: 41
view all 5 authors...
Abstract Background Low-molecular-weight heparins (LMWH) are the drug of choice for treatment of cancer-associated thrombosis (CAT), however non-vitamin K antagonist oral anticoagulants (NOAC) seem to be a reasonable alternative. We investigated the safety and efficacy of NOAC versus LMWH in patients with a history of CAT. Methods In a prospective cohort study 128 consecutive patients with active cancer who experienced CAT were enrolled following LMWH treatment for ≥3 months. Symptomatic recurre...